NICE has upheld its decision not to recommend Alzheimer’s treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025, before final recommendations are issued.
Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
